ACM
MRNA icon

ADAR1 Capital Management’s Moderna MRNA Stock Holding History

ADAR1 Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,000
Closed -$594K – 319
2024
Q2 		$594K Buy
+5,000
New +$633K 0.11% 91

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ADAR1 Capital Management's MRNA Position: Q1 2025 in Review

ADAR1 Capital Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 9,000 shares — an estimated $374K sold.

ADAR1 Capital Management first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $374K in Q4 2024. 694 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • ADAR1 Capital Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 9,000 Moderna shares in Q1 2025, an estimated $374K.
  • ADAR1 Capital Management first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
  • ADAR1 Capital Management's Moderna position peaked at $374K in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.